التفاصيل البيبلوغرافية
| العنوان: |
A new opportunity after migraine treatment failure? |
| المؤلفون: |
Charles, Andrew1 acharles@ucla.edu |
| المصدر: |
Lancet. 11/24/2018, Vol. 392 Issue 10161, p2241-2242. 2p. |
| مصطلحات موضوعية: |
*RESEARCH, CLINICAL trials, MIGRAINE, PRIMARY headache disorders, CALCITONIN gene-related peptide, NEUROPEPTIDES, DRUG efficacy, PATIENT compliance, COMPARATIVE studies, RESEARCH methodology, MEDICAL cooperation, MONOCLONAL antibodies, EVALUATION research, TREATMENT effectiveness, BLIND experiment |
| مستخلص: |
The article focuses on a new opportunity following treatment failure of migraine preventive therapy due to poor efficacy or tolerability, which is an all too common problem in clinical practice. It highlightis a 12-week, randomised, double-blind, placebo-controlled, phase 3b study which addresses migraine treatment failure and the efficacy of erenumab, a monoclonal antibody targeting calcitonin gene-related peptide. |
| قاعدة البيانات: |
Business Source Index |
